Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2023-04-25 Legal Proceedings Report
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Updates
Legal Proceedings Report Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details ongoing legal proceedings and settlements related to antitrust and consumer protection lawsuits involving the company. The content focuses on legal matters and settlement amounts, with no financial statements or report data. The document length is 3965 characters, which is relatively short and reads as an announcement rather than a full report. It does not contain financial results, management discussion, or audit information. Therefore, it fits best under Legal Proceedings Report (LTR) category, which covers updates on significant lawsuits and regulatory actions involving the company.
2023-04-25 English
Updates
Legal Proceedings Report Classification · 95% confidence The document is a formal letter addressed to stock exchanges and regulatory bodies, disclosing information about ongoing legal proceedings and a settlement agreement related to antitrust lawsuits. It references Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, which pertains to disclosure of material events. The content focuses on legal matters and settlement details, without any financial statements or report data. The document length is 3174 characters, which is relatively short and primarily serves as a disclosure notice. Therefore, it fits best under Legal Proceedings Report (LTR) as it updates on significant lawsuits involving the company.
2023-04-19 English
Shareholders meeting
Regulatory Filings
2023-04-14 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for a specific pharmaceutical product. It is addressed to stock exchanges and includes a request to take the announcement on record. The content focuses on the approval news and market data, without any financial statements, detailed financial performance, or regulatory filings. The document length is 4372 characters, which is relatively short and typical for a press release or announcement. There is no indication that this is an annual report, earnings release, or any other detailed financial or regulatory report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories such as earnings release or capital update.
2023-03-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for a specific drug. It is a media release intended for public and regulatory record, not a financial report or detailed filing. The document is short (3981 characters) and includes a request to take the announcement on record. There are no financial statements, management discussion, or regulatory certifications. This fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-03-20 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received acceptance from the U.S. FDA on its IND application to proceed with a clinical study. It is addressed to stock exchanges and includes a media release. The content is an announcement of a regulatory milestone related to drug development, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed report content. The document is short (4719 characters) and serves as a public announcement of a corporate event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.